Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for difficult-to-treat infections MARINA DEL REY, Calif., August 01, 2022 /PRNewswire/ -- Armata...

Click to view original post